Estimation of minimum clinically important difference for pain in fibromyalgia
dc.contributor.author | Mease, Philip J. | en_US |
dc.contributor.author | Spaeth, Michael | en_US |
dc.contributor.author | Clauw, Daniel J. | en_US |
dc.contributor.author | Arnold, Lesley M. | en_US |
dc.contributor.author | Bradley, Laurence A. | en_US |
dc.contributor.author | Russell, I. Jon | en_US |
dc.contributor.author | Kajdasz, Daniel K. | en_US |
dc.contributor.author | Walker, Daniel J. | en_US |
dc.contributor.author | Chappell, Amy S. | en_US |
dc.date.accessioned | 2011-11-10T15:37:26Z | |
dc.date.available | 2012-07-12T17:42:24Z | en_US |
dc.date.issued | 2011-06 | en_US |
dc.identifier.citation | Mease, Philip J.; Spaeth, Michael; Clauw, Daniel J.; Arnold, Lesley M.; Bradley, Laurence A.; Russell, I. Jon; Kajdasz, Daniel K.; Walker, Daniel J.; Chappell, Amy S. (2011). "Estimation of minimum clinically important difference for pain in fibromyalgia ." Arthritis Care & Research 63(6): 821-826. <http://hdl.handle.net/2027.42/87063> | en_US |
dc.identifier.issn | 2151-464X | en_US |
dc.identifier.issn | 2151-4658 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/87063 | |
dc.description.abstract | Objective To estimate the minimum clinically important difference (MCID) for several pain measures obtained from the Brief Pain Inventory (BPI) for patients with fibromyalgia. Methods Data were pooled across 12‐week treatment periods from 4 randomized, double‐blind, placebo‐controlled studies designed to evaluate the safety and efficacy of duloxetine for the treatment of fibromyalgia. Each study enrolled subjects with American College of Rheumatology–defined fibromyalgia who presented with moderate to severe pain. The MCIDs for the BPI average pain item score and the BPI severity score (the mean of the BPI pain scale values: right now, average, least, and worst) were estimated by anchoring against the Patient's Global Impressions of Improvement scale. Results The anchor‐based MCIDs for the BPI average pain item and severity scores were 2.1 and 2.2 points, respectively. These MCIDs correspond to 32.3% and 34.2% reductions from baseline in scores. Conclusion In these analyses, the MCIDs for several pain measures obtained from the BPI were similar (∼2 points) and corresponded to a 30–35% improvement from baseline to end point. These findings may be beneficial for use in designing clinical trials in which the BPI is used to evaluate improvements in pain severity. | en_US |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.title | Estimation of minimum clinically important difference for pain in fibromyalgia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor | en_US |
dc.contributor.affiliationother | Swedish Medical Center and University of Washington School of Medicine, Seattle | en_US |
dc.contributor.affiliationother | Practice for Internal Medicine, Graefelfing, Munich, Germany | en_US |
dc.contributor.affiliationother | University of Cincinnati College of Medicine, Cincinnati, Ohio | en_US |
dc.contributor.affiliationother | University of Alabama at Birmingham | en_US |
dc.contributor.affiliationother | University of Texas Health Science Center, San Antonio | en_US |
dc.contributor.affiliationother | Trovis Pharmaceuticals LLC, New Haven, Connecticut | en_US |
dc.contributor.affiliationother | Lilly Research Laboratories, Indianapolis, Indiana | en_US |
dc.contributor.affiliationother | Lilly Research Laboratories and Indiana University School of Medicine, Indianapolis | en_US |
dc.contributor.affiliationother | Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104 | en_US |
dc.identifier.pmid | 21312349 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/87063/1/20449_ftp.pdf | |
dc.identifier.doi | 10.1002/acr.20449 | en_US |
dc.identifier.source | Arthritis Care & Research | en_US |
dc.identifier.citedreference | Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, et al. Fibromyalgia syndrome. J Rheumatol 2005; 32: 2270 – 7. | en_US |
dc.identifier.citedreference | DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998; 86: 102 – 6. | en_US |
dc.identifier.citedreference | Melzack R. The short‐form McGill Pain Questionnaire. Pain 1987; 30: 191 – 7. | en_US |
dc.identifier.citedreference | Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728 – 33. | en_US |
dc.identifier.citedreference | Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129 – 38. | en_US |
dc.identifier.citedreference | Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double‐blind, placebo‐controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5 – 15. | en_US |
dc.identifier.citedreference | Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6‐month, randomized, double‐blind, placebo‐controlled, fixed‐dose trial. Pain 2008; 136: 432 – 44. | en_US |
dc.identifier.citedreference | Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six‐month double‐blind, placebo‐controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008; 1: 91 – 102. | en_US |
dc.identifier.citedreference | Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double‐blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974 – 84. | en_US |
dc.identifier.citedreference | Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15‐week, multicenter, randomized, double‐blind, placebo‐controlled, multiple‐dose clinical trial. Clin Ther 2008; 30: 1988 – 2004. | en_US |
dc.identifier.citedreference | Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. J Rheumatol 2009; 36: 398 – 409. | en_US |
dc.identifier.citedreference | Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6‐month, double‐blind, placebo‐controlled trial with pregabalin. Pain 2008; 136: 419 – 31. | en_US |
dc.identifier.citedreference | Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14‐week, randomized, double‐blinded, placebo‐controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008; 9: 792 – 805. | en_US |
dc.identifier.citedreference | Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407 – 15. | en_US |
dc.identifier.citedreference | Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002; 14: 109 – 14. | en_US |
dc.identifier.citedreference | Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007; 7: 541 – 6. | en_US |
dc.identifier.citedreference | Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, et al. Minimal clinically important differences: review of methods. J Rheumatol 2001; 28: 406 – 12. | en_US |
dc.identifier.citedreference | Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105 – 21. | en_US |
dc.identifier.citedreference | Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare publication (ADM). Rockville (MD): National Institute of Mental Health; 1976. p. 76 – 338. | en_US |
dc.identifier.citedreference | Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160 – 72. | en_US |
dc.identifier.citedreference | Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale. Pain 2001; 94: 149 – 58. | en_US |
dc.identifier.citedreference | Demyttenaere K, Bonnewyn A, Bruffaerts R, Brugha T, de Graaf R, Alonso J. Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking. J Affect Disord 2006; 92: 185 – 93. | en_US |
dc.identifier.citedreference | Garcia‐Cebrian A, Gandhi P, Demyttenaere K, Peveler R. The association of depression and painful physical symptoms: a review of the European literature. Eur Psychiatry 2006; 21: 379 – 88. | en_US |
dc.identifier.citedreference | Jordan K, Dunn KM, Lewis M, Croft P. A minimal clinically important difference was derived for the Roland‐Morris Disability Questionnaire for low back pain. J Clin Epidemiol 2006; 59: 45 – 52. | en_US |
dc.identifier.citedreference | Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine 2005; 30: 1331 – 4. | en_US |
dc.identifier.citedreference | Cleland JA, Childs JD, Whitman JM. Psychometric properties of the Neck Disability Index and Numeric Pain Rating Scale in patients with mechanical neck pain. Arch Phys Med Rehabil 2008; 89: 69 – 74. | en_US |
dc.identifier.citedreference | Hagg O, Fritzell P, Nordwall A, for the Swedish Lumbar Spine Study Group. The clinical importance of changes in outcome scores after treatment for chronic low back pain. Eur Spine J 2003; 12: 12 – 20. | en_US |
dc.identifier.citedreference | Sim J, Jordan K, Lewis M, Hill J, Hay EM, Dziedzic K. Sensitivity to change and internal consistency of the Northwick Park Neck Pain Questionnaire and derivation of a minimal clinically important difference. Clin J Pain 2006; 22: 820 – 6. | en_US |
dc.identifier.citedreference | Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A. The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 2010; 11: 109 – 18. | en_US |
dc.identifier.citedreference | Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesis or antidepressant effect? Int Clin Psychopharmacol 2006; 21: 311 – 7. | en_US |
dc.identifier.citedreference | Perahia DG, Quail D, Desaiah D, Montejo AL, Schatzberg AF. Switching to duloxetine in selective serotonin reuptake inhibitor non‐ and partial‐responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009; 43: 512 – 8. | en_US |
dc.identifier.citedreference | Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007; 34: 1188 – 93. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.